In 2005 the European Respiratory Society (ERS), in collaboration with The European Society for Clinical Microbiology and Infectious Diseases (ESCMID), published guidelines on the management of lower respiratory tract infections (LRTI) in adults [1]. This document was based on published scientific literature up to the end of 2002. We have now updated these guidelines to include publications to May 2010. The Taskforce responsible for guideline development has been sponsored by the ERS and ESCMID. Members of the Taskforce are members of the sponsoring ERS and/or ESCMID.
Our objective is to provide evidence-based recommendations for the most common management questions occurring in routine clinical practice in the management of adult patients with LRTI. The target audience for the guidelines is thus all those whose routine practice includes the management of adult LRTI.
This document begins with definitions and background sections on microbial cause, resistance and pharmacokinetics/pharmacodynamics, with conventional referencing. The guideline section captures management outside hospital, management inside hospital (including community-acquired pneumonia (CAP), acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and acute exacerbations of bronchiectasis) and prevention. The guidelines are about the management of infection. This means that for conditions such as AECOPD, aspects of management that are unreleated to infection (e.g. use of steroids or bronchodilators) are not included. It contains the graded recommendations but also the background information for each recommendation, with details about each new cited reference and the evidence grades. Because this is an update, original data and publications have usually not been repeated and the reader is referred to the original publication for this. As this is an update using the same methodologies, the layout of the document, including text, recommendations and evidence tables, is the same as in 2005.
下呼吸道感染吃什么药 2011欧洲下呼吸道感染攻略
精彩推荐
- 中汽研实测满分认证!鸿蒙智行全系安全硬实力破局行业乱象

随着辅助驾驶功能从高端车型的专属配置逐步下沉为新能源汽车的标配选项,消费者对这项技术的关注点始终聚焦于最核心的安全性上。然而,近年来频发的辅助驾驶相关事故、各第...详细
- 辅助驾驶测评标准趋严,鸿蒙智行以安全表现树立行业标杆

近年来,随着智能汽车快速发展,辅助驾驶功能逐渐成为消费者选车的重要参考。然而,由于第三方测评标准不一、测试方法各异,导致评测结果往往难以横向比较,甚至引发公众对...详细
- 主动防护+被动硬实力,问界新M5 Ultra和Model Y谁能护全家周全?

最近不少家庭和中高端用户开始将目光锁定在智能SUV市场。在众多车型中,有两款尤为引人关注:一款是华为深度赋能的问界新M5 Ultra,另一款则是长期占据话题榜的特斯拉Model...详细
- 从“可用”到“好用且安全”:华为乾崑智驾ADS 4的进阶逻辑

在智能驾驶技术加速落地的今天,行业正面临一个关键命题:如何让辅助驾驶真正从能用跨越到好用且安全?市场上不乏宣称具备高阶智驾能力的产品,但多数仍停留在特定场景下的...详细
本周热门
- 同仁堂健康双十一活动开启 “象食养医”倡导从健康的时候就关注健康

如果你想了解自己身体的秘密,让健康成为日常的生活方式,保持年轻的状态,实现抗衰老,逆生长的美好愿望,那么今年双十一的这场活动你一定不要错过。11月1日,同仁堂健康...详细





